Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moxifloxacin + oseltamivir + piperacillin + tazobactam
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination of four drugs: moxifloxacin (a fluoroquinolone antibiotic), oseltamivir (an antiviral medication), and piperacillin-tazobactam (a combination penicillin antibiotic with a beta-lactamase inhibitor). Studies have shown synergistic bactericidal activity when moxifloxacin is combined with piperacillin-tazobactam against various gram-negative bacteria including Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii. The combination demonstrated enhanced bactericidal activity compared to either agent used alone.
02
Targets
Beyond the preview
Go deeper on moxifloxacin + oseltamivir + piperacillin + tazobactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moxifloxacin + oseltamivir + piperacillin + tazobactam.